12:00 AM
 | 
Apr 25, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Tykerb regulatory update

GlaxoSmithKline submitted an MAA to EMA for Tyverb lapatinib to treat patients with metastatic breast cancer whose tumors overexpress epidermal growth factor receptor 2 ( EGFR2;...

Read the full 122 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >